Indeed, Chaperonin-containing TCP1 subunit 2 (CCT2), which high levels were found significantly associated to adverse outcome in BC patients, can be delivered, through small EVs, to CD4 + T cells and suppress their activation via CD40L downmodulation [51]. The gene discussed is CCT2; the disease is breast cancer.